Applied Genetic Technologies Corporation (AGTC), a clinical-stage biotechnology company, develops gene therapy products for inherited orphan ophthalmology diseases.
AGTC's lead product candidates in the preclinical stage comprise treatments for X-linked retinoschisis, Congenital Achromatopsia, and X-linked retinitis pigmentosa, which are diseases of the eye caused by mutations in single genes. It also has completed preclinical proof-of-concept studies, and Phase I and Phase II clinical trials of a treatment for alpha-1 antitrypsin deficiency, an inherited orphan lung disease. In addition, the company has proof-of-concept programs for other eye diseases, such as leber congenital amaurosis (type 2), and wet form of age-related macular degeneration. It has strategic collaboration agreements with SAFC Pharma; and 4D Molecular Therapeutics.
The company was founded in 1999 and is headquartered in Alachua, Florida.
August 22, 2018
RegMed Investors’ (RMi) pre-open: low volume initiates another round of highs, which sooner not later will get sold into
August 17, 2018
RegMed Investors’ (RMi) pre-open: the sector is what it is, until it isn’t and even then it doesn’t seem to be…
August 16, 2018
RegMed Investors’ (RMi) closing bell: the sector had the wind at its back
August 15, 2018
RegMed Investors’ (RMi) closing bell: the sector stumbled
August 13, 2018
RegMed Investors’ (RMi) closing bell: the sector got squeezed
August 10, 2018
RegMed Investors’ (RMi) closing bell; the sector seemed immune from market‘s edginess
August 9, 2018
RegMed Investors’ (RMi) closing bell; the impact of August, earnings, low volume and high volatility
August 7, 2018
RegMed Investors’ (RMi) pre-open: far from the finish line
August 6, 2018
RegMed Investors’ (RMi) closing bell; catch and release is also about share price weighing
August 3, 2018
RegMed Investors’ (RMi) closing bell; the remains of the week – a wreck
35 companies, 1 interpreter!
Insight, foresight and recommendation
Applied Genetics Technology Corporations (AGTC) In Q1/16, AGTC has clinical trial timing issues and spending woes – until clinical results are announced which are slow due to enrollments ...
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.